Good evening :)
Place Order
Add to Watchlist

Eris Lifesciences Ltd

ERIS

Eris Lifesciences Ltd

ERIS
Health CarePharmaceuticals
SmallcapWith a market cap of ₹18,023 cr, stock is ranked 385
Moderate RiskStock is 2.03x as volatile as Nifty
1,350.601.55% (+20.60)
1,350.601.55% (+20.60)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹18,023 cr, stock is ranked 385
Moderate RiskStock is 2.03x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹18,023 cr, stock is ranked 385
Moderate RiskStock is 2.03x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
47.395.59—
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.916.640.47%

Forecast & Ratings

Detailed Forecast 
89%
Analysts have suggested that investors can buy this stock

from 9 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Eris Lifesciences Limited is engaged in manufacturing, marketing and selling of generics within the chronic and acute categories of the Indian Pharmaceutical Market

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 15.46%, vs industry avg of 9.03%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 0.46% to 0.55%

Lower than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 6.15%, vs industry avg of 15.28%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue600.39774.61882.011,013.851,089.461,220.571,373.131,743.832,080.102,286.71
Raw Materialssubtract89.94107.73136.92167.12150.12276.44259.29348.53379.321,507.18
Power & Fuel Costsubtract3.593.023.173.454.623.954.165.7012.04
Employee Costsubtract124.67131.22157.32190.66205.69229.30250.18346.16403.82
Selling & Administrative Expensessubtract189.79204.42224.28279.66238.82210.94256.10375.66426.75
Operating & Other expensessubtract17.3333.9711.81-3.80106.3060.4992.28119.88159.52
Depreciation/Amortizationsubtract20.3622.7625.6436.3550.2642.9964.71117.09182.61217.65
Interest & Other Itemssubtract0.281.1010.6523.062.301.984.2226.1784.80127.82
Taxes & Other Itemssubtract20.8823.6018.1226.5634.8639.3636.0822.4839.2653.77
EPS9.7117.9521.3921.1521.7026.1529.8928.1128.8227.96
DPS6.040.000.000.002.875.506.017.35—0.00
Payout ratio0.620.000.000.000.130.210.200.260.000.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2022

Annual report

PDF

Investor Presentation

May 3PDF
Feb 2PDF
Jan 28PDF
+2 more
FY 2023

Annual report

PDF

Investor Presentation

May 17PDF
Jan 17PDF
Oct 20PDF
Aug 5PDF
FY 2024

Annual report

PDF

Investor Presentation

Aug 7PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Eris Lifesciences Ltd45.985.59—
Sun Pharmaceutical Industries Ltd48.196.880.70%
Cipla Ltd32.685.020.78%
Torrent Pharmaceuticals Ltd68.9816.660.83%

Price Comparison

Compare ERIS with any stock or ETF
Compare ERIS with any stock or ETF
ERIS
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding54.88%14.52%1.71%14.59%14.30%

Sep 2023

Dec 2023

Mar 2024

Jun 2024

Shareholding History

MarJunSepDec '23MarJun9.64%10.27%13.86%13.85%14.92%14.52%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Eris Lifesciences Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
HDFC Small Cap Fund - Growth - Direct Plan

Growth
4.8411%2.57%0.53%7/91 (+39)
HDFC Hybrid Equity Fund - Growth - Direct Plan

Growth
1.7775%1.30%0.32%23/135 (+3)
Franklin India Smaller Companies Fund - Growth - Direct Plan

Growth
1.4378%1.80%0.55%8/99 (+12)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Eris Lifesciences Ltd

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateAug 11, 2022

Interim
Interim | Div/Share: ₹7.35

Dividend/Share

₹7.35

Ex DateEx Date

Aug 11, 2022

Cash Dividend

Ex DateEx DateAug 5, 2021

Interim
Interim | Div/Share: ₹6.01

Dividend/Share

₹6.01

Ex DateEx Date

Aug 5, 2021

Cash Dividend

Ex DateEx DateAug 13, 2020

Interim
Interim | Div/Share: ₹5.50

Dividend/Share

₹5.50

Ex DateEx Date

Aug 13, 2020

Cash Dividend

Ex DateEx DateMar 19, 2020

Interim
Interim | Div/Share: ₹2.87

Dividend/Share

₹2.87

Ex DateEx Date

Mar 19, 2020

News & Opinions
Corporate
ERIS Lifesciences to convene AGM

ERIS Lifesciences announced that the 18th Annual General Meeting (AGM) of the company will be held on 25 September 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live

Eris Lifesciences net profit drops 4.5% to Rs 89 crore in Q1FY25

2 months agoEconomic Times

Eris Lifesciences Q1 Results: Net dips 4.5% YoY at Rs 89 crore

2 months agoEconomic Times

ERIS Lifesciences consolidated net profit declines 12.31% in the June 2024 quarter

2 months agoBusiness Standard
Earnings
ERIS Lifesciences consolidated net profit declines 12.31% in the June 2024 quarter

Net profit of ERIS Lifesciences declined 12.31% to Rs 83.18 crore in the quarter ended June 2024 as against Rs 94.86 crore during the previous quarter ended June 2023. Sales rose 55.55% to Rs 715.59 crore in the quarter ended June 2024 as against Rs 460.03 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales715.59460.03 56 OPM %34.9336.90 - PBDT191.26153.38 25 PBT115.32112.49 3 NP83.1894.86 -12 Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
ERIS Lifesciences announces board meeting date

ERIS Lifesciences will hold a meeting of the Board of Directors of the Company on 2 August 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live

2 top stock recommendations from Aditya Arora

2 months agoEconomic Times

Praj Delta Corp Trading strategies for 5 overbought NSE smallcap stocks

3 months agoBusiness Standard

Eris Lifesciences Q4 Results Review - Healthy Execution, Addition Of Business Drive The Quarter: Motilal Oswal

4 months agoBloomberg Quint
Brands Wil Be Exclusive To Eris, Co Will Have Right To Commercialise These Brands: Biocon Biologics
6 months agoCNBC-TV18